Das Epigenom

详细信息    查看全文

• 作者：A. Leipold ; J. Heß ; K. Zaoui
• 关键词：DNA ; methyltransferase ; Epigenetics ; Histone deacetylase ; Squamous cell carcinoma ; Therapy
• 刊名：HNO
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：63
• 期：11
• 页码：786-791
• 全文大小：452 KB
• 参考文献：1.Anayannis NV, Schlecht NF, Belbin TJ (2015) Epigenetic mechanisms of human papillomavirus-associated head and neck cancer. Arch Pathol Lab Med. doi: 10.5858/arpa.2014-0554-RA (Epub ahead of print)
  2.Azad N, Zahnow CA, Rudin CM et al (2013) The future of epigenetic therapy in solid tumours – lessons from the past. Nature reviews. Clin Oncol 10:256–266
  3.Baylin SB (2011) Resistance, epigenetics and the cancer ecosystem. Nat Med 17:288–289CrossRef PubMed
  4.Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome – biological and translational implications. Nature reviews. Cancer 11:726–734PubMedCentral PubMed
  5.Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769–784CrossRef PubMed
  6.Brieger J, Mann SA, Pongsapich W et al (2012) Pharmacological genome demethylation increases radiosensitivity of head and neck squamous carcinoma cells. Int J Mol Med 29:505–509PubMed
  7.Bruzzese F, Leone A, Rocco M et al (2011) HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 226:2378–2390CrossRef PubMed
  8.Chang HH, Chiang CP, Hung HC et al (2009) Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol 45:610–614CrossRef PubMed
  9.Chang X, Monitto CL, Demokan S et al (2010) Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res 70:2870–2879PubMedCentral CrossRef PubMed
  10.Chen X, Liu L, Mims J et al (2015) Analysis of DNA methylation and gene expression in radiation-resistant head and neck tumors. Epigenetics 10:545–561CrossRef PubMed
  11.Chikamatsu K, Ishii H, Murata T et al (2013) Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck. Cancer Sci 104:1468–1475CrossRef PubMed
  12.D’costa ZJ, Jolly C, Androphy EJ et al (2012) Transcriptional repression of E-cadherin by human papillomavirus type 16 E6. Plos One 7:e48954PubMedCentral CrossRef PubMed
  13.De Craene B, Berx G (2013) Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13:97–110CrossRef PubMed
  14.Edwards AM, Isserlin R, Bader GD et al (2011) Too many roads not taken. Nature 470:163–165CrossRef PubMed
  15.Erdmann A, Halby L, Fahy J et al (2015) Targeting DNA methylation with small molecules: what’s next. J Med Chem 58:2569–2583CrossRef PubMed
  16.Erlich RB, Kherrouche Z, Rickwood D et al (2012) Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma. Br J Cancer 106:107–115PubMedCentral CrossRef PubMed
  17.Fernandez AF, Esteller M (2010) Viral epigenomes in human tumorigenesis. Oncogene 29:1405–1420CrossRef PubMed
  18.Gan CP, Hamid S, Hor SY et al (2012) Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. Head Neck 34:344–353CrossRef PubMed
  19.Giudice FS, Pinto DS Jr, Nor JE et al (2013) Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer. Plos One 8:e58672PubMedCentral CrossRef PubMed
  20.Gray JE, Haura E, Chiappori A et al (2014) A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. Clin Cancer Res 20:1644–1655PubMedCentral CrossRef PubMed
  21.Haberland M, Montgomery RL, Olson EN (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10:32–42PubMedCentral CrossRef PubMed
  22.Hehlgans S, Storch K, Lange I et al (2013) The novel HDAC inhibitor NDACI054 sensitizes human cancer cells to radiotherapy. Radiother Oncol 109:126–132CrossRef PubMed
  23.Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683–692PubMedCentral CrossRef PubMed
  24.Khan O, La Thangue NB (2012) HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 90:85–94CrossRef PubMed
  25.Koffler J, Sharma S, Hess J (2014) Predictive value of epigenetic alterations in head and neck squamous cell carcinoma. Mol Cell Oncol 1:e954827
  26.Kumar B, Yadav A, Lang JC et al (2015) Suberoylanilide hydroxamic acid (SAHA) reverses chemoresistance in head and neck cancer cells by targeting cancer stem cells via the downregulation of nanog. Genes Cancer 6:169–181PubMedCentral PubMed
  27.Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27:5459–5468CrossRef PubMed
  28.Lechner M, Fenton T, West J et al (2013) Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma. Genome Med 5:15PubMedCentral CrossRef PubMed
  29.Marks PA (2007) Discovery and development of SAHA as an anticancer agent. Oncogene 26:1351–1356CrossRef PubMed
  30.Network CGA (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517:576–582CrossRef
  31.Parfenov M, Pedamallu CS, Gehlenborg N et al (2014) Characterization of HPV and host genome interactions in primary head and neck cancers. Proceedings of the National Academy of Sciences of the United States of America Bd. 111., S 15544–15549
  32.Rodriguez-Paredes M, Esteller M (2011) Cancer epigenetics reaches mainstream oncology. Nat Med 17:330–339CrossRef PubMed
  33.Subramaniam D, Thombre R, Dhar A et al (2014) DNA Methyltransferases: a novel target for prevention and therapy. Front Oncol 4:80PubMedCentral CrossRef PubMed
  34.Theocharis S, Klijanienko J, Giaginis C et al (2011) Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. J Oral Pathol Med 40:706–714CrossRef PubMed
  35.Van Kempen PM, Noorlag R, Braunius WW et al (2014) Differences in methylation profiles between HPV-positive and HPV-negative oropharynx squamous cell carcinoma: a systematic review. Epigenetics 9:194–203PubMedCentral CrossRef PubMed
  36.Viet CT, Dang D, Achdjian S et al (2014) Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma. Plos One 9:e112880PubMedCentral CrossRef PubMed
  37.West AC, Johnstone RW (2014) New and emerging HDAC inhibitors for cancer treatment. J Clin Investig 124:30–39PubMedCentral CrossRef PubMed
  38.You JS, Jones PA (2012) Cancer genetics and epigenetics: two sides of the same coin. Cancer Cell 22:9–20PubMedCentral CrossRef PubMed
  39.Zentner GE, Henikoff S (2013) Regulation of nucleosome dynamics by histone modifications. Nat Struct Mol Biol 20:259–266CrossRef
  
• 作者单位：A. Leipold (1)
  J. Heß (1)
  K. Zaoui (1)
  
  1. Sektion Experimentelle und Translationale Kopf-Hals-Onkologie, Hals-Nasen-Ohrenklinik, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Deutschland
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Otorhinolaryngology
  Neurosurgery
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-0458

文摘

Background The pathogenesis of head and neck squamous carcinoma (HNSCC) is a complex and multistage process, which is characterized by the accumulation of genetic and epigenetic aberrations. Most of our knowledge concerning the regulation of gene expression by the epigenome is based on changes in DNA methylation and post-translational histone modifications that affect the phenotypic plasticity of cells under physiological and pathological conditions.